Andere Kunden interessierten sich auch für
![Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis]( "Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis")
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis20,99 €![Roadmap to Prevent and Combat Drug-Resistant Tuberculosis]( "Roadmap to Prevent and Combat Drug-Resistant Tuberculosis")
Roadmap to Prevent and Combat Drug-Resistant Tuberculosis33,99 €![The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the Brics]( "The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the Brics")
The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the Brics53,99 €![Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge]( "Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge")
Tuberculosis - India is fighting for elimination: Weaker private sector in managing TB: Drug Resistant TB - a big challenge35,99 €![The Treatment of Tuberculosis]( "The Treatment of Tuberculosis")
The Treatment of Tuberculosis33,99 €![Tuberculosis Control in the Western Pacific Region]( "Tuberculosis Control in the Western Pacific Region")
Tuberculosis Control in the Western Pacific Region26,99 €![Electronic Recording and Reporting for Tuberculosis Care and Control]( "Electronic Recording and Reporting for Tuberculosis Care and Control")
Electronic Recording and Reporting for Tuberculosis Care and Control39,99 €
The emergence of drug resistance is a major threat to global tuberculosis (TB) care and control. The World Health Organization (WHO) estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) cases (i.e. resistant to, at least, rifampicin and isoniazid) occur each year globally. Current treatment regimens for MDR-TB are far from satisfactory: the overall duration is 20 months or more, requiring daily administration of drugs that are more toxic and less effective than those used to treat drug-susceptible TB, and have a high cost. Among MDR-TB patients started on treatment globally in 2009, only 48% were treated successfully, largely as a result of a high frequency of patient deaths (15%) and loss to follow-up (28%), which is commonly associated with adverse drug reactions, among other factors. In a subset of 200 extensively drug-resistant tuberculosis (XDR-TB) patients in 14 countries, treatment success reached only 33% overall and 26% of the patients died. New drugs that would help build a better, safer, less toxic, shorter and cheaper regimen are therefore urgently needed to reduce patient suffering and mortality. This document provides interim guidance for the use of bedaquiline in conjunction with other WHO-recommended MDR-TB treatments. It also specifies the essential treatment and management conditions for the use of this drug. The main audiences are national TB control programs (NTP), other public health agencies, and other public and private partners involved in planning, implementing and monitoring MDR-TB control activities. The principles and recommendations are also relevant for specialist clinicians, technical advisers, laboratory technicians, drug procurement managers, other service providers, other relevant government officials, and implementing partners involved in country-level MDR-TB service strengthening. Individuals responsible for program planning, budgeting, resource mobilization, and training activities for MDR-TB diagnostic services may also benefit from this guidance.